TrialSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2014

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Nadera J Sweiss et al.PubMed ↗Full text ↗

No numbers read from the abstract.